Literature DB >> 28795381

Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine.

Jiao Guo1.   

Abstract

Hyperlipidemia, type 2 diabetes mellitus, nonalcoholic fatty liver and many other metabolic disorder are frequently co-existing in patients. In addition, these diseases are closely related in pathophysiological settings. However, increasing of the disease incidence, lacking of comprehensive prevention and control measurements against the key pathology point concomitant occurrence with the pattern of the single disease, single target therapy, that is leading therapeutic strategy for these metabolic disorders in the setting of Western medicine (WM). On the basis of the combination of the advantages of integrated Chinese medicine (CM) and WM, with unified understanding of such diseases, the new concept of glucolipid metabolic disease (GLMD) is introduced. In this new concept, disorders in glucose and lipid metabolism are recognized as the key trigger and major driving force for the progress of GLMD. The key points of pathology included dysfunction of neuronal-endocrine-immune system, insulin resistance, oxidative stress, inflammation and intestinal flora imbalance. In the core pathogenic perspective of CM, it can be explained as "Gan (Liver) Shi Shu Xie" (dysfunction of Gan in metabolism and emotion regulation) that will lead to the occurence/production of endogenous dampness and phlegm, blood stasis and turbid. This leads to the new concept of "Liver-based regulatory system for metabolic homeostasis" to be introduced further. The comprehensive prevention and control strategy "Tiao Gan Qi Shu Hua Zhuo" (modulating Gan, trigging key metabolic system to resolve pathogenic factors such as phlegm retention and dampness). Its representative formula Fufang Zhenzhu Tiaozhi Capsule () is innovated under such rationales. Comment for some commonly-used CM GLMD therapeutic drugs was presented. High-level evidence-based and epidemiological and mechanism studies should be carried out to further interpret and explain of the scientific connotation of GLMD.

Entities:  

Keywords:  Chinese medicine; Tiao Gan (Liver) Qi Shu Hua Zhuo (modulating Gan; glucolipid metabolic disease; liver-based regulatory system for metabolic homeostasis; trigging key metabolic system to resolve pathogenic factors such as phlegm retention and dampness)

Mesh:

Substances:

Year:  2017        PMID: 28795381     DOI: 10.1007/s11655-017-2811-3

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  25 in total

1.  Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects.

Authors:  Auni Juutilainen; Seppo Lehto; Tapani Rönnemaa; Kalevi Pyörälä; Markku Laakso
Journal:  Diabetes Care       Date:  2005-12       Impact factor: 19.112

2.  FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting.

Authors:  Qingning Liang; Ling Zhong; Jialiang Zhang; Yu Wang; Stefan R Bornstein; Chris R Triggle; Hong Ding; Karen S L Lam; Aimin Xu
Journal:  Diabetes       Date:  2014-07-14       Impact factor: 9.461

Review 3.  Metabolic sensing and the brain: who, what, where, and how?

Authors:  Barry E Levin; Christophe Magnan; Ambrose Dunn-Meynell; Christelle Le Foll
Journal:  Endocrinology       Date:  2011-04-26       Impact factor: 4.736

Review 4.  Small lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2.

Authors:  Yu Wang
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

5.  Betatrophin: a hormone that controls pancreatic β cell proliferation.

Authors:  Peng Yi; Ji-Sun Park; Douglas A Melton
Journal:  Cell       Date:  2013-04-25       Impact factor: 41.582

6.  Effects of Fufang Zhenzhu Tiaozhi Prescription (), A Chinese herbal preparation, on atherosclerosis in ApoE-/- mice and related mechanisms.

Authors:  Fu-Tian Tang; Jiao Guo; Wei He; Li-Jing Wang; Duo-Sheng Luo; Wei-Jian Bei
Journal:  Chin J Integr Med       Date:  2011-08-01       Impact factor: 1.978

Review 7.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

8.  A new TCM formula FTZ lowers serum cholesterol by regulating HMG-CoA reductase and CYP7A1 in hyperlipidemic rats.

Authors:  Jiao Guo; Weijian Bei; Yinming Hu; Chunping Tang; Wei He; Xiaobo Liu; Lihua Huang; Yang Cao; Xuguang Hu; Xunlong Zhong; Le Cao
Journal:  J Ethnopharmacol       Date:  2011-03-17       Impact factor: 4.360

9.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

10.  Banting lecture 2011: hyperinsulinemia: cause or consequence?

Authors:  Barbara E Corkey
Journal:  Diabetes       Date:  2012-01       Impact factor: 9.461

View more
  13 in total

Review 1.  Therapy to Obese Type 2 Diabetes Mellitus: How Far Will We Go Down the Wrong Road?

Authors:  Xian-Pei Heng; Xiu-Jun Li; Liang Li; Liu-Qing Yang; Zi-Ta Wang; Su-Ping Huang
Journal:  Chin J Integr Med       Date:  2018-10-17       Impact factor: 1.978

2.  Biochemical and Endocrine Parameters for the Discrimination and Calibration of Bipolar Disorder or Major Depressive Disorder.

Authors:  Yuncheng Zhu; Haifeng Ji; Zhiang Niu; Hongmei Liu; Xiaohui Wu; Lu Yang; Zuowei Wang; Jun Chen; Yiru Fang
Journal:  Front Psychiatry       Date:  2022-06-20       Impact factor: 5.435

3.  Hotspot Analysis of Traditional Drugs in Diabetes Treatment Literature.

Authors:  Hui Shen; Wei-Kai Zhu; Zhi Lu; Hai-Cheng Zhou
Journal:  Chin J Integr Med       Date:  2020-09-30       Impact factor: 1.978

Review 4.  Research Progress on Non-Drug Treatment for Blood Glucose Control of Type 2 Diabetes Mellitus.

Authors:  Jun-Ping Wei; Qiu-Hong Wang; Hui-Juan Zheng; Fan Wei
Journal:  Chin J Integr Med       Date:  2018-07-25       Impact factor: 1.978

5.  Breviscapine alleviates NASH by inhibiting TGF-β-activated kinase 1-dependent signaling.

Authors:  Tian Lan; Shuo Jiang; Jing Zhang; Qiqing Weng; Yang Yu; Haonan Li; Song Tian; Xin Ding; Sha Hu; Yiqi Yang; Weixuan Wang; Lexun Wang; Duosheng Luo; Xue Xiao; Shenghua Piao; Qing Zhu; Xianglu Rong; Jiao Guo
Journal:  Hepatology       Date:  2021-12-19       Impact factor: 17.298

6.  FTZ Ameliorates Diabetic Cardiomyopathy by Inhibiting Inflammation and Cardiac Fibrosis in the Streptozotocin-Induced Model.

Authors:  Lexun Wang; Huijuan Wu; Yanyue Deng; Shengxi Zhang; Quxing Wei; Qianqian Yang; Shenghua Piao; Weijian Bei; Xianglu Rong; Jiao Guo
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-28       Impact factor: 2.629

7.  Mechanism of Astragalus membranaceus Alleviating Acquired Hyperlipidemia Induced by High-Fat Diet through Regulating Lipid Metabolism.

Authors:  Ling Wang; Wenya Zheng; Jinxin Yang; Anwar Ali; Hong Qin
Journal:  Nutrients       Date:  2022-02-23       Impact factor: 5.717

8.  The Traditional Chinese Medicine Formula FTZ Protects against Cardiac Fibrosis by Suppressing the TGFβ1-Smad2/3 Pathway.

Authors:  Yue Zhang; Dongwei Wang; Kaili Wu; Xiaoqi Shao; Hongtao Diao; Zhiying Wang; Mengxian Sun; Xueying Huang; Yun Li; Xinyuan Tang; Meiling Yan; Jiao Guo
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-19       Impact factor: 2.650

9.  The outcomes of patients with diabetes mellitus in The Philippine CORONA Study.

Authors:  Adrian I Espiritu; Harold Henrison C Chiu; Marie Charmaine C Sy; Veeda Michelle M Anlacan; Roland Dominic G Jamora
Journal:  Sci Rep       Date:  2021-12-24       Impact factor: 4.379

10.  The Efficacy and Safety of Chinese Medicine Fufang Zhenzhu Tiaozhi Capsule (FTZ) in the Treatment of Diabetic Coronary Heart Disease: Study Protocol for Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  Lexun Wang; Lei Xiang; Shenghua Piao; Xiao Gong; Wanxing Zhou; Weixun Feng; Huilin Li; Leyu Li; Aisheng Wei; Qing Zhu; Xianglu Rong; Jiao Guo
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-14       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.